Information for medicine and pack size:
Solu-Cortef 100 mg powder for injection, 5 vials

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

INDICATIONS AS AT 15/12/2004: When oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, SOLU-CORTEF powder for injection is indicated for intravenous or intramuscular use in the following conditions: 1. ENDOCRINE DISORDERS: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralcorticoids where applicable; in infancy, mineralcorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralcorticoid supplements may be necessary, particularly when synthetic analogues are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcaemia associated with cancer. RHEUMATIC DISORDERS: As an adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute non-specific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. COLLAGEN DISEASES: During an exacerbation or as maintenance therapy in selected cases of: Systematic lupus erythematosus. Systematic dermatomyositis (polymyositis). Acute rheumatic carditis. DERMATOLOGICAL DISEASES: Pemphigus. Severe erythema multiforme (Stevens-Johnson Syndrome). Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrhoeic dermatitis. Severe psoriasis. Mycosis fungoides. ALLERGIC STATES: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Drug hypersensitivity reactions. Contact dermatitis. Urticarial transfusion reactions. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Acute non-infectious laryngeal oedema (adrenaline is the drug of first choice). OPTHALMIC DISEASES: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Allergic corneal marginal ulcers. Keratitis. GASTROINTESTINAL DISEASES: To tide the patient over a critical period of the disease in : Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). RESPIRATORY DISEASES: Symptomatic sarcoidosis. Loeffler's Syndrome not manageable by other means. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Aspiration pneumonitis. HAEMATOLOGICAL DISORERS: Acquired (autoimmune) haemolytic anaemia. Erythroblastopenia (RBC anaemia). Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Congenital (erythroid) hypoplastic anaemia. NEOPLASTIC DISEASES: For palliative management of: Leukaemia's and lymphomas in adults. Acute childhood leukaemia. OEDMATOUS STATES: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus. NERVOUS SYSTEM: Acute exacerbations of multiple sclerosis. MISCELLANEOUS: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurological or myocardial involvement.

Table of characteristics

There is one type of pack available.

We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site